To examine whether sVCAM-1 promotes gemcitabine resistance in pancreatic cancer in vivo, we treated VCAM-1-overexpressing allograft tumors or control tumors with gemcitabine. This evidence concerns the gene VCAM1 and familial pancreatic carcinoma.